

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Jian DING et al.  
Title: SERUM BIOMARKERS IN ISCHAEMIC HEART DISEASE  
Int'l. Appl. No.: PCT/US2004/017624  
Int'l. Filing Date: 6/4/2004  
Examiner: Unassigned  
Art Unit: Unassigned

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

**TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b), within three (3) months of the filing date of the application.

RELEVANCE OF EACH DOCUMENT

The documents being cited in the attached PTO/SB/08 were cited as being relevant during the prosecution of the corresponding international application. A copy of the International Search Report is attached setting forth the portion of the documents considered relevant by the examiner. A copy of the cited references listed in the Search Report are not being submitted herewith.

Applicants respectfully request that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date: 6 December 2005

By: S. A. Bent

FOLEY & LARDNER LLP

Customer Number: **54077**

Telephone: (202) 672-5404

Facsimile: (202) 672-5399

Stephen A. Bent

Attorney for Applicant

Registration No. 29,768

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Date Submitted: December 6, 2005

(use as many sheets as necessary)

Sheet 1 of 1

Application Number

Unassigned

Filing Date

December 6, 2005

First Named Inventor

Jian DING

Group Art Unit

Unassigned 1641

Examiner Name

Unassigned

J. Grun

Attorney Docket Number

035394-0306

IP9 Rec'd PCT/PTO 06 DEC 2005

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
/JLG/	A1	US 2002/076738 A1		Jong WOO HEE	6/20/2002	
/JLG/	A2	US 2002/155513 A1		Christopher DOWLING et al.	10/24/2002	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>				

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>6</sup>
	A3	H. J. ISSAQ et al., "The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, Academic Press, San Diego, Ca., U.S., vol. 292, no. 3, 4/5/2002 pp. 587-592.		
	A4	Kouichi OZAKI et al., "Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotxin-alpha secretion in vitro", NATURE, May 6, 2004, vol. 429, no. 6987, May 6, 2004, pp. 72-75.		
	A5	F-T LIU et al., "Intracellular functions of galectins", BBA - GENERAL SUBJECTS, ELSEVIER SCIENCE PUBLISHERS, NL., vol. 1572, no. 2-3, 9/19/2002, pp. 263-273.		
	A6	G.A. RABINOVICH et al., "Role of galectins in inflammatory and immunomodulatory processes", BBA - GENERAL SUBJECTS, ELSEVIER SCIENCE PUBLISHERS, NL., vol. 1572, no. 2-3, September 19, 2002, pp. 274-284.		
		(Copies not provided.)		

Examiner Signature	/James L. Grun/	Date Considered	06/05/2008
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.